There has been a six-fold increase in the number of antibiotics being popped by Indians. This includes the retail sale of Carbapenems -- powerful class IV antibiotics, typically used as a "last resort" to treat serious infections caused by multi-drug resistant, gram-negative pathogens. Research by the Centre for Disease Dynamics, Economics and Policy, Washington DC, has found that retail sale of carbapenems increased six times -- from 0.21 units per million...

The Medical Council of India (MCI) has decided to take stern action against doctors who had endorsed scientific recommendations submitted to the Central Drugs Standard Control Organization (CDSCO), which were written by drug companies themselves. TOI reported on Thursday how drug companies have been caught red-handed writing scientific recommendations of their own drugs and submitting them to the Drug Controller General of India (DCGI) after getting them endorsed by reputed doctors...

-The Hindu Business Line The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land. The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that “invisible hands” of drug-makers were involved in getting favourable reports on medicines...

Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...